Manager TitleAgeSince
Chief Executive Officer 64 2022-03-30
Director of Finance/CFO - 2024-07-31
Director TitleAgeSince
Chairman 70 2019-11-19
Director/Board Member 65 2013-05-31
Director/Board Member 80 2021-12-29
Date Insider Type Main position Quantity % Market Cap.
22-06-21Free 111,193 0.2314%
21-01-18Sell 2,000 0.0179%
21-01-18Sell 1 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-.--% - - 817K
-0.53%+1.67%+19.19%-20.47% 63.09B
-0.43%+2.32%+51.36%+215.67% 55.61B
+0.07%+38.60%+38.60%+38.60% 41.64B
-2.36%-1.25%-52.13%-58.98% 38.98B
+1.19%+2.74%+58.64%-29.02% 29.82B
-1.11%-6.58%+122.45%-49.58% 23.71B
-0.86%+9.48%+59.19%+72.19% 21.48B
-1.25%-0.27%-4.39%+142.42% 16.87B
-2.53%+3.15%+65.04%+120.58% 16.74B
Average -8.21%+2.98%+39.77%+47.93% 34.22B
Weighted average by Cap. -0.59%+2.91%+34.36%+45.27%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
50
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SPEX Stock